Halozyme Therapeutics Inc. [NASDAQ: HALO] slipped around -3.42 points on Tuesday, while shares priced at $42.68 at the close of the session, down -7.42%. The company report on May 11, 2021 that Halozyme Reports First Quarter 2021 Results.
– First Quarter Revenue of $89.0 million, Up from $25.4 million in First Quarter of 2020 -.
– Record Quarterly Royalties in the First Quarter of $36.9 million Representing 119% Growth over First Quarter 2020 -.
Halozyme Therapeutics Inc. stock is now -0.07% down from its year-to-date (YTD) trading value. HALO Stock saw the intraday high of $45.00 and lowest of $41.09 per share. The company’s 52-week high price is 56.40, which means current price is +10.00% above from all time high which was touched on 02/24/21.
Compared to the average trading volume of 1.37M shares, HALO reached a trading volume of 2215530 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Halozyme Therapeutics Inc. [HALO]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HALO shares is $49.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HALO stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Halozyme Therapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 11, 2021. While these analysts kept the previous recommendation, The Benchmark Company raised their target price from $46 to $59. The new note on the price target was released on January 21, 2021, representing the official price target for Halozyme Therapeutics Inc. stock. Previously, the target price had yet another raise to $50, while Berenberg analysts kept a Buy rating on HALO stock.
The Average True Range (ATR) for Halozyme Therapeutics Inc. is set at 1.73, with the Price to Sales ratio for HALO stock in the period of the last 12 months amounting to 22.91. The Price to Book ratio for the last quarter was 38.11, with the Price to Cash per share for the same quarter was set at 2.56. Price to Free Cash Flow for HALO in the course of the last twelve months was 115.69 with Quick ratio for the last quarter at 1.20.
How has HALO stock performed recently?
Halozyme Therapeutics Inc. [HALO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -11.95. With this latest performance, HALO shares dropped by -0.63% in over the last four-week period, additionally plugging by 13.24% over the last 6 months – not to mention a rise of 71.96% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HALO stock in for the last two-week period is set at 32.05, with the RSI for the last a single of trading hit 20.79, and the three-weeks RSI is set at 38.81 for Halozyme Therapeutics Inc. [HALO]. The present Moving Average for the last 50 days of trading for this stock 44.85, while it was recorded at 46.37 for the last single week of trading, and 38.49 for the last 200 days.
Halozyme Therapeutics Inc. [HALO]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Halozyme Therapeutics Inc. [HALO] shares currently have an operating margin of +53.91 and a Gross Margin at +83.79. Halozyme Therapeutics Inc.’s Net Margin is presently recorded at +48.24.
Return on Total Capital for HALO is now 27.67, given the latest momentum, and Return on Invested Capital for the company is 41.25. Return on Equity for this stock inclined to 106.33, with Return on Assets sitting at 22.53. When it comes to the capital structure of this company, Halozyme Therapeutics Inc. [HALO] has a Total Debt to Total Equity ratio set at 262.98. Additionally, HALO Total Debt to Total Capital is recorded at 72.45, with Total Debt to Total Assets ending up at 68.50.
Reflecting on the efficiency of the workforce at the company, Halozyme Therapeutics Inc. [HALO] managed to generate an average of $949,154 per employee. Receivables Turnover for the company is 3.41 with a Total Asset Turnover recorded at a value of 0.47.Halozyme Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.30.
Earnings analysis for Halozyme Therapeutics Inc. [HALO]
With the latest financial reports released by the company, Halozyme Therapeutics Inc. posted 0.19/share EPS, while the average EPS was predicted by analysts to be reported at 0.25/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -24.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HALO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Halozyme Therapeutics Inc. go to 44.00%.
Insider trade positions for Halozyme Therapeutics Inc. [HALO]
There are presently around $5,913 million, or 98.40% of HALO stock, in the hands of institutional investors. The top three institutional holders of HALO stocks are: BLACKROCK INC. with ownership of 18,437,478, which is approximately -0.237% of the company’s market cap and around 0.70% of the total institutional ownership; VANGUARD GROUP INC, holding 13,149,703 shares of the stock with an approximate value of $561.23 million in HALO stocks shares; and ARTISAN PARTNERS LIMITED PARTNERSHIP, currently with $446.78 million in HALO stock with ownership of nearly 1.789% of the company’s market capitalization.
Positions in Halozyme Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 198 institutional holders increased their position in Halozyme Therapeutics Inc. [NASDAQ:HALO] by around 15,056,297 shares. Additionally, 145 investors decreased positions by around 12,403,266 shares, while 29 investors held positions by with 111,091,686 shares. The mentioned changes placed institutional holdings at 138,551,249 shares, according to the latest SEC report filing. HALO stock had 65 new institutional investments in for a total of 2,937,235 shares, while 38 institutional investors sold positions of 2,297,802 shares during the same period.